financetom
Business
financetom
/
Business
/
Elastic, PagerDuty, UiPath Face Growth, Revenue Hurdles, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elastic, PagerDuty, UiPath Face Growth, Revenue Hurdles, Morgan Stanley Says
May 30, 2025 9:14 AM

11:48 AM EDT, 05/30/2025 (MT Newswires) -- Elastic (ESTC), PagerDuty ( PD ) and UiPath ( PATH ) face slow new-business growth and revenue erosion amid flat demand for core products, sales-execution headwinds and cautious customer spending, despite improvements in operational profitability and margins, Morgan Stanley said Friday in a report.

Elastic is experiencing cloud growth deceleration and a cautious fiscal year 2026 outlook, driven by conservative assumptions from a new chief financial officer, following solid Q4 results, the report said.

Still, the company's AI Search momentum remains intact with growing adoption and strong monetization potential heading into fiscal 2027, the report said.

Morgan Stanley cut its price target on Elastic's stock to $115 from $120 and maintained its overweight rating.

PagerDuty's ( PD ) profitability and cash flow strength are countered by new business growth challenges tied to sales execution issues, the report said.

Morgan Stanley rates PagerDuty ( PD ) equal weight with a price target of $17.

UiPath ( PATH ) continues to face challenges in generating new business with net new annual recurring revenue declining for six straight quarters, Morgan Stanley said. While early product momentum may support future growth, near-term trends remain under pressure, the report said.

Morgan Stanley rates UiPath ( PATH ) equal weight with a price target of $12.

Elastic and PagerDuty ( PD ) shares both fell 11% in recent trading Friday, and UiPath ( PATH ) rose 0.6%.

Price: 82.34, Change: -9.70, Percent Change: -10.53

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AES Corp beats Q2 profit estimates on favorable weather
AES Corp beats Q2 profit estimates on favorable weather
Aug 1, 2024
Aug 1 (Reuters) - AES Corp ( AES ) beat Wall Street estimates for second-quarter profit on Thursday, as the electric utility benefited from customers using more electricity to deal with a hot summer and new renewables projects. The Virginia-based company saw considerable growth in its renewables unit last year, benefiting from a global push to adopt cleaner power generation...
Boeing's new CEO Kelly Ortberg faces a major overhaul, from factories to finances 
Boeing's new CEO Kelly Ortberg faces a major overhaul, from factories to finances 
Aug 1, 2024
* Ortberg's priorities include mending relationships with airlines and employees * Boeing ( BA ) faces production and delivery challenges * Threat of labor disruptions looms By Allison Lampert Aug 1 (Reuters) - Boeing's ( BA ) incoming boss, Kelly Ortberg, faces a herculean task when he starts next week - restoring the might of a U.S. corporate powerhouse rocked...
Walgreens further reduces stake in Cencora
Walgreens further reduces stake in Cencora
Aug 1, 2024
Aug 1 (Reuters) - Walgreens Boots Alliance ( WBA ) said on Thursday it has sold shares in drug distributor Cencora ( COR ) for proceeds of about $1.1 billion. Walgreens' ownership of Cencora ( COR ) has now decreased from about 12% to about 10%, it said. Walgreens has sold shares worth $818 million and Cencora ( COR )...
Mettler-Toledo forecast dull third-quarter profit on weak China demand
Mettler-Toledo forecast dull third-quarter profit on weak China demand
Aug 1, 2024
Aug 1 (Reuters) - Medical equipment maker Mettler-Toledo International ( MTD ) forecast third-quarter profit below estimates on Thursday, a sign of a weaker-than-expected recovery in sales in its key market China. Lifesciences firms including lab equipment maker Mettler-Toledo ( MTD ) have seen sluggish demand for their instruments used in drug development as cash-strapped biotech clients try to navigate...
Copyright 2023-2026 - www.financetom.com All Rights Reserved